25 August 2026 AstraZeneca prices €2.55 billion bond offering AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering)....
19 August 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 17 August 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to the Company's Chief Financial Officer, Dr Aradhana Sarin, under the AstraZeneca Performance Share Plan (the AZPSP)....
17 August 2026 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu is the first and only HER2-directed medicine to improve...
17 August 2026 Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemotherapy in patients with metastatic non-small cell...
17 August 2026 Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results...
3 August 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
3 August 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 July 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,033,389 ordinary shares of US$0.25. No shares are held in Treasury....
31 July 2026 Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy Approval based on TROPION-Breast02 Phase III trial results where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and...
27 July 2026 Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant High-level results from the ALXN1210-TMA-313 Phase III clinical trial showed that Ultomiris (ravulizumab) did not achieve statistical significance for the primary endpoint of event-free survival through 26...
27 July 2026 Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting...
27 July 2026 AstraZeneca results: H1 and Q2 2026 Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 Revenue and EPS summary [][][] H1 2026 % Change Q2 2026 % Change $m Actual CER[1] $m Actual CER - Product Sales 28,896 8 5 14,510 5 4 - Alliance Revenue 1,699 31 29 874 34 33 Product Revenue 30,595 9 6 15,384 6 5...
23 July 2026 Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation First and only next-generation oral...
14 July 2026 AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Complements AstraZeneca’s leading portfolio of medicines targeting EGFR mutations Zegfrovy is approved in the US and China to treat lung cancer patients whose tumours carry exon 20 insertion mutations...
[This announcement contains inside information] 9 July 2026 Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not...
1 July 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
1 July 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 June 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,024,534 ordinary shares of US$0.25. No shares are held in Treasury....
29 June 2026 Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which demonstrated clinically meaningful responses across a broad range of tumours...
29 June 2026 Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Recommendation based on TROPION-Breast02 Phase III trial where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful...
15 June 2026 Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed Truqap combination reduced risk of radiographic disease progression or death by 19% First-in-class AKT...
1 June 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
1 June 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,009,750 ordinary shares of US$0.25. No shares are held in Treasury....
29 May 2026 Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of Imfinzi added to BCG vs....